VUNO Introduces VUNO Med-DeepCARS at 'HIMS 2024'... "U.S. Launch Within the Year"

Medical AI company VUNO announced on the 4th that it will participate in the world's largest medical IT exhibition, the '2024 HIMSS Global Health Exhibition (HIMSS 2024),' held in Orlando, Florida, USA, from the 11th to the 15th, showcasing its AI-based cardiac arrest prediction medical device, VUNO Med-DeepCARS. VUNO plans to launch VUNO Med-DeepCARS in the United States in the second half of this year.

Vuno announced on the 4th that it will participate in the world's largest medical IT exhibition, 'HIMSS 2024'.

HIMSS 2024 is the world's largest medical IT technology event organized by the Healthcare Information and Management Systems Society (HIMSS) in the United States. Every year, more than 30,000 healthcare industry professionals and ICT company representatives from around the world participate to share the latest technology trends and business information. This year, more than 1,100 companies are expected to participate in the exhibition.

VUNO will focus on introducing its AI-based cardiac arrest prediction medical device, VUNO Med-DeepCARS. At the exhibition booth, it will share use cases from domestic medical sites and present key research achievements, including a multi-center clinical study paper that demonstrated clinical efficacy through the product's first prospective study. Additionally, VUNO plans to explore new business opportunities through meetings with hospital officials and buyers from various countries attending the event.

VUNO Med-DeepCARS is the first medical AI product in Korea to be designated as a breakthrough device by the U.S. Food and Drug Administration (FDA). The company aims to obtain FDA approval and officially launch the product within this year. VUNO Med-DeepCARS is an AI medical device that analyzes four vital signs?respiration, blood pressure, pulse, and body temperature?routinely measured for inpatients in general wards, providing a risk score for cardiac arrest occurrence within 24 hours. It enables proactive responses by medical staff in general wards where continuous monitoring of all inpatients is challenging.

Lee Yeha, CEO of VUNO, said, “At our first participation in HIMSS 2024, we are proud to introduce the excellence and clinical value of VUNO Med-DeepCARS, our flagship product. We will continue our efforts to ensure that VUNO Med-DeepCARS, which protects patient safety and fills medical gaps in clinical settings, rapidly spreads as an essential medical device overseas soon.”

This content was produced with the assistance of AI translation services.